Upon examination, diagnosed with severe ophthalmoparesis, history of acute failure to thrive in infancy, severe increased variability in muscle fiber diameter manifestation were noted. Further imaging and laboratory tests identified gene variant c.679C>T p.R227W and c.2542G>A p.G848S. The patient was started on a tailored therapeutic plan.
Upon examination, presence of acute abdominal distention were noted. Further imaging and laboratory tests identified gene variant 1399G→A (A467T). The patient was started on a tailored therapeutic plan.
A medical history of severe ophthalmoparesis manifestation, chronic developmental regression observed was documented. Genetic analysis confirmed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Supportive care and follow-up were recommended.
The individual was admitted with complaints of persistent abdominal distention, history of episodic ophthalmoparesis, history of moderate cerebral atrophy, episodic ascites. Laboratory evaluations detected gene variant Tyr955Cys. Clinical monitoring is ongoing.
The patient presented to the clinic with chronic distal upper limb muscle weakness observed. Diagnostic workup revealed gene variant 1399G>A A467T and 3573G>T K1191N. Treatment was initiated accordingly.
A medical history of diagnosed with mild cerebral atrophy, acute abdominal distention manifestation, intermittent failure to thrive in infancy detected, distal upper limb muscle weakness manifestation was documented. Genetic analysis confirmed gene variant c3239G>C p.Ser1080Thr. Supportive care and follow-up were recommended.
Upon examination, diagnosed with severe developmental regression, clinical signs of episodic distal upper limb muscle weakness, persistent hearing impairment observed were noted. Further imaging and laboratory tests identified gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with clinical signs of acute generalized hypotonia. Diagnostic workup revealed gene variant c3239G>C p.Ser1080Thr. Treatment was initiated accordingly.
The patient presented to the clinic with clinical signs of acute cerebral atrophy, presence of sudden hearing impairment, severe abdominal distention, developmental regression condition. Diagnostic workup revealed gene variant p.W748S and p.T914P. Treatment was initiated accordingly.
Upon examination, history of acute generalized hypotonia, episodic ophthalmoparesis observed were noted. Further imaging and laboratory tests identified gene variant c.679C>T p.R227W and c.2542G>A p.G848S. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of intermittent cerebral atrophy detected, persistent ophthalmoparesis condition, chronic developmental regression. Laboratory evaluations detected gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Clinical monitoring is ongoing.
The patient presented to the clinic with clinical signs of acute cerebral atrophy, intermittent developmental regression symptoms, generalized hypotonia, clinical signs of chronic hearing impairment. Diagnostic workup revealed gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). Treatment was initiated accordingly.
The individual was admitted with complaints of chronic cerebral atrophy observed, clinical signs of episodic hearing impairment, presence of moderate ophthalmoparesis. Laboratory evaluations detected gene variant c.752C>T p.T251I and c.1760C>T p.P587L. Clinical monitoring is ongoing.
Initial symptoms included clinical signs of moderate ascites, progressive failure to thrive in infancy detected, clinical signs of acute generalized hypotonia, clinical signs of moderate distal upper limb muscle weakness. Subsequent investigations showed gene variant p.A467T and c.2157+5_6GC>AG. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with sudden failure to thrive in infancy manifestation, clinical signs of increased variability in muscle fiber diameter. Diagnostic workup revealed gene variant R853W and G737R. Treatment was initiated accordingly.
A medical history of mild distal upper limb muscle weakness, progressive developmental regression manifestation, history of moderate ascites was documented. Genetic analysis confirmed gene variant W748S. Supportive care and follow-up were recommended.
Upon examination, presence of severe generalized hypotonia, progressive ascites symptoms were noted. Further imaging and laboratory tests identified gene variant C752T (T251I) and C1760T (P587L). The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with chronic abdominal distention. Diagnostic workup revealed gene variant 1399G→A (A467T). Treatment was initiated accordingly.
Initial symptoms included acute developmental regression observed. Subsequent investigations showed gene variant c.3286C>T (p.Arg1096Cys). Management involved both pharmacological and rehabilitative approaches.
A medical history of history of severe abdominal distention, presence of acute cerebral atrophy was documented. Genetic analysis confirmed . Supportive care and follow-up were recommended.
A medical history of chronic increased variability in muscle fiber diameter manifestation was documented. Genetic analysis confirmed . Supportive care and follow-up were recommended.
Initial symptoms included presence of chronic developmental regression. Subsequent investigations showed gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included presence of acute distal upper limb muscle weakness, persistent failure to thrive in infancy symptoms. Subsequent investigations showed gene variant A467T. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of mild ophthalmoparesis, presence of severe developmental regression, ascites symptoms, intermittent increased variability in muscle fiber diameter observed. Laboratory evaluations detected gene variant c.1535A>T p.K512M. Clinical monitoring is ongoing.
The individual was admitted with complaints of intermittent hearing impairment. Laboratory evaluations detected gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Clinical monitoring is ongoing.
Initial symptoms included persistent increased variability in muscle fiber diameter, history of progressive generalized hypotonia, presence of severe ophthalmoparesis. Subsequent investigations showed gene variant c3239G>C p.Ser1080Thr. Management involved both pharmacological and rehabilitative approaches.
Upon examination, persistent increased variability in muscle fiber diameter detected, history of chronic cerebral atrophy, mild ascites condition, sudden distal upper limb muscle weakness detected were noted. Further imaging and laboratory tests identified gene variant P765T. The patient was started on a tailored therapeutic plan.
Initial symptoms included diagnosed with chronic failure to thrive in infancy, clinical signs of severe developmental regression, presence of severe distal upper limb muscle weakness. Subsequent investigations showed gene variant C752T (T251I) and C1760T (P587L). Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included presence of progressive developmental regression, clinical signs of acute generalized hypotonia, history of mild ophthalmoparesis, presence of chronic increased variability in muscle fiber diameter. Subsequent investigations showed gene variant P765T. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with mild hearing impairment, episodic failure to thrive in infancy symptoms, developmental regression symptoms. Diagnostic workup revealed gene variant A467T and W748S. Treatment was initiated accordingly.
The patient presented to the clinic with sudden ascites detected, episodic cerebral atrophy observed, presence of chronic failure to thrive in infancy. Diagnostic workup revealed gene variant c.2993C>T p.998S>L and c.3550G>C p.1184D>H. Treatment was initiated accordingly.
The patient presented to the clinic with chronic distal upper limb muscle weakness condition, moderate hearing impairment. Diagnostic workup revealed gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Treatment was initiated accordingly.
A medical history of clinical signs of severe ascites, increased variability in muscle fiber diameter symptoms was documented. Genetic analysis confirmed gene variant C752T (T251I) and C1760T (P587L). Supportive care and follow-up were recommended.
Upon examination, diagnosed with moderate hearing impairment, history of progressive ophthalmoparesis, clinical signs of persistent ascites, intermittent cerebral atrophy detected were noted. Further imaging and laboratory tests identified gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of history of chronic cerebral atrophy, history of progressive ophthalmoparesis, abdominal distention observed, presence of mild generalized hypotonia. Laboratory evaluations detected gene variant c. 2243G>C (p. W748S). Clinical monitoring is ongoing.
Initial symptoms included intermittent generalized hypotonia symptoms, presence of progressive failure to thrive in infancy, intermittent increased variability in muscle fiber diameter observed, diagnosed with progressive abdominal distention. Subsequent investigations showed gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Management involved both pharmacological and rehabilitative approaches.
Upon examination, persistent developmental regression condition were noted. Further imaging and laboratory tests identified gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with history of episodic abdominal distention, persistent developmental regression symptoms, history of intermittent ascites, moderate distal upper limb muscle weakness condition. Diagnostic workup revealed gene variant 1399G>A A467T and 3573G>T K1191N. Treatment was initiated accordingly.
The patient presented to the clinic with history of severe increased variability in muscle fiber diameter. Diagnostic workup revealed . Treatment was initiated accordingly.
Initial symptoms included moderate hearing impairment. Subsequent investigations showed gene variant c.1399G>A (p.A467T) and c.3285C>G (p.S1095R). Management involved both pharmacological and rehabilitative approaches.
A medical history of diagnosed with mild failure to thrive in infancy, clinical signs of mild generalized hypotonia, moderate cerebral atrophy manifestation was documented. Genetic analysis confirmed gene variant c.1535A>T p.K512M. Supportive care and follow-up were recommended.
Initial symptoms included history of moderate increased variability in muscle fiber diameter, abdominal distention manifestation, clinical signs of developmental regression. Subsequent investigations showed gene variant C752T (T251I) and C1760T (P587L). Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included generalized hypotonia condition, history of chronic increased variability in muscle fiber diameter, episodic cerebral atrophy condition. Subsequent investigations showed gene variant c.1288A>T and c.2752T>C. Management involved both pharmacological and rehabilitative approaches.
Upon examination, history of moderate abdominal distention, persistent failure to thrive in infancy symptoms, history of distal upper limb muscle weakness were noted. Further imaging and laboratory tests identified gene variant A467T and W748S. The patient was started on a tailored therapeutic plan.
A medical history of clinical signs of moderate ascites was documented. Genetic analysis confirmed gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Supportive care and follow-up were recommended.
The individual was admitted with complaints of clinical signs of generalized hypotonia, chronic failure to thrive in infancy condition, presence of distal upper limb muscle weakness, history of persistent ophthalmoparesis. Laboratory evaluations detected gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. Clinical monitoring is ongoing.
The patient presented to the clinic with diagnosed with sudden failure to thrive in infancy, sudden cerebral atrophy, moderate distal upper limb muscle weakness observed, history of increased variability in muscle fiber diameter. Diagnostic workup revealed gene variant A467T. Treatment was initiated accordingly.
Initial symptoms included history of mild generalized hypotonia. Subsequent investigations showed gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with mild hearing impairment observed, clinical signs of moderate ascites. Diagnostic workup revealed gene variant c3239G>C p.Ser1080Thr. Treatment was initiated accordingly.
Initial symptoms included clinical signs of chronic cerebral atrophy, moderate developmental regression symptoms, presence of distal upper limb muscle weakness. Subsequent investigations showed gene variant Tyr955Cys. Management involved both pharmacological and rehabilitative approaches.
A medical history of clinical signs of moderate cerebral atrophy, diagnosed with chronic abdominal distention, mild failure to thrive in infancy observed, presence of acute ophthalmoparesis was documented. Genetic analysis confirmed gene variant 1399G→A (A467T). Supportive care and follow-up were recommended.
A medical history of diagnosed with intermittent hearing impairment, mild increased variability in muscle fiber diameter, generalized hypotonia symptoms was documented. Genetic analysis confirmed gene variant W748S and c.3643+2T>C. Supportive care and follow-up were recommended.
The patient presented to the clinic with clinical signs of progressive ascites, acute cerebral atrophy manifestation, moderate generalized hypotonia observed, progressive developmental regression. Diagnostic workup revealed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Treatment was initiated accordingly.
The individual was admitted with complaints of history of moderate hearing impairment. Laboratory evaluations detected gene variant A467T and W748S. Clinical monitoring is ongoing.
Initial symptoms included clinical signs of progressive abdominal distention, mild failure to thrive in infancy manifestation. Subsequent investigations showed gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of acute generalized hypotonia manifestation, clinical signs of episodic developmental regression. Laboratory evaluations detected gene variant c.1399G>A (p.A467T) and c.3285C>G (p.S1095R). Clinical monitoring is ongoing.
Initial symptoms included history of failure to thrive in infancy, sudden increased variability in muscle fiber diameter observed. Subsequent investigations showed gene variant c.2993C>T p.998S>L and c.3550G>C p.1184D>H. Management involved both pharmacological and rehabilitative approaches.
A medical history of clinical signs of sudden ascites was documented. Genetic analysis confirmed gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Supportive care and follow-up were recommended.
Upon examination, increased variability in muscle fiber diameter observed were noted. Further imaging and laboratory tests identified . The patient was started on a tailored therapeutic plan.
Upon examination, progressive developmental regression manifestation, progressive ophthalmoparesis observed, history of mild abdominal distention were noted. Further imaging and laboratory tests identified gene variant c.2993C>T p.998S>L and c.3550G>C p.1184D>H. The patient was started on a tailored therapeutic plan.
A medical history of severe failure to thrive in infancy symptoms, history of chronic hearing impairment was documented. Genetic analysis confirmed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Supportive care and follow-up were recommended.
A medical history of ascites symptoms was documented. Genetic analysis confirmed gene variant Tyr955Cys. Supportive care and follow-up were recommended.
The patient presented to the clinic with diagnosed with chronic failure to thrive in infancy, chronic hearing impairment. Diagnostic workup revealed gene variant c.2993C>T p.998S>L and c.3550G>C p.1184D>H. Treatment was initiated accordingly.
The patient presented to the clinic with moderate developmental regression condition, abdominal distention manifestation, chronic ophthalmoparesis manifestation. Diagnostic workup revealed gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Treatment was initiated accordingly.
Upon examination, progressive cerebral atrophy observed, moderate ascites, presence of episodic increased variability in muscle fiber diameter were noted. Further imaging and laboratory tests identified gene variant c.2584G>A p.A862T and c.830A>T p.H277L. The patient was started on a tailored therapeutic plan.
Initial symptoms included chronic increased variability in muscle fiber diameter symptoms. Subsequent investigations showed gene variant c.679C>T p.R227W and c.2542G>A p.G848S. Management involved both pharmacological and rehabilitative approaches.
Upon examination, acute failure to thrive in infancy observed, episodic ascites, acute generalized hypotonia manifestation were noted. Further imaging and laboratory tests identified gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). The patient was started on a tailored therapeutic plan.
Initial symptoms included episodic ascites condition, moderate failure to thrive in infancy, presence of persistent abdominal distention. Subsequent investigations showed gene variant C752T (T251I) and C1760T (P587L). Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with severe distal upper limb muscle weakness observed, intermittent ascites, persistent developmental regression. Diagnostic workup revealed gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). Treatment was initiated accordingly.
The patient presented to the clinic with acute hearing impairment symptoms, episodic ophthalmoparesis detected. Diagnostic workup revealed gene variant W748S and c.3643+2T>C. Treatment was initiated accordingly.
The individual was admitted with complaints of sudden generalized hypotonia manifestation. Laboratory evaluations detected gene variant W748S. Clinical monitoring is ongoing.
Upon examination, chronic cerebral atrophy, diagnosed with mild hearing impairment, episodic ophthalmoparesis manifestation, presence of intermittent generalized hypotonia were noted. Further imaging and laboratory tests identified gene variant 1399G >A A467T and 2243G >C W748S. The patient was started on a tailored therapeutic plan.
Upon examination, abdominal distention symptoms, sudden ophthalmoparesis manifestation were noted. Further imaging and laboratory tests identified gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. The patient was started on a tailored therapeutic plan.
Initial symptoms included progressive developmental regression manifestation, failure to thrive in infancy, history of intermittent cerebral atrophy. Subsequent investigations showed gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of history of severe ascites, history of cerebral atrophy, acute ophthalmoparesis observed. Laboratory evaluations detected gene variant c.2584G>A p.A862T and c.830A>T p.H277L. Clinical monitoring is ongoing.
Upon examination, sudden abdominal distention symptoms, severe hearing impairment condition, history of intermittent generalized hypotonia were noted. Further imaging and laboratory tests identified gene variant c.3102delG (p.Lys1035Serfs*59) and c.3286C>T (p.Arg1096Cys). The patient was started on a tailored therapeutic plan.
Upon examination, abdominal distention, clinical signs of chronic increased variability in muscle fiber diameter, sudden ascites manifestation were noted. Further imaging and laboratory tests identified . The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with history of sudden ascites, clinical signs of cerebral atrophy, intermittent generalized hypotonia observed. Diagnostic workup revealed gene variant c.1535A>T p.K512M. Treatment was initiated accordingly.
The patient presented to the clinic with episodic increased variability in muscle fiber diameter condition, clinical signs of chronic abdominal distention, acute failure to thrive in infancy, progressive distal upper limb muscle weakness. Diagnostic workup revealed . Treatment was initiated accordingly.
The patient presented to the clinic with severe ascites, mild increased variability in muscle fiber diameter, intermittent hearing impairment detected, acute failure to thrive in infancy symptoms. Diagnostic workup revealed gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Treatment was initiated accordingly.
A medical history of presence of severe developmental regression, severe distal upper limb muscle weakness condition, mild cerebral atrophy, diagnosed with acute failure to thrive in infancy was documented. Genetic analysis confirmed gene variant (c.2542G > A) p.G848S and (c.1399G > A) p.A467T. Supportive care and follow-up were recommended.
Upon examination, clinical signs of sudden generalized hypotonia, episodic increased variability in muscle fiber diameter detected, persistent ophthalmoparesis observed, sudden developmental regression symptoms were noted. Further imaging and laboratory tests identified gene variant c.3643+1G>A and c.2396C>A (p.S799Y). The patient was started on a tailored therapeutic plan.
A medical history of severe increased variability in muscle fiber diameter observed, diagnosed with sudden ophthalmoparesis, severe developmental regression condition was documented. Genetic analysis confirmed gene variant p.A467T and c.2157+5_6GC>AG. Supportive care and follow-up were recommended.
Upon examination, presence of episodic cerebral atrophy, acute ascites detected, history of severe abdominal distention, acute hearing impairment symptoms were noted. Further imaging and laboratory tests identified gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of mild abdominal distention condition, clinical signs of progressive failure to thrive in infancy, episodic ascites manifestation. Laboratory evaluations detected gene variant c.2993C>T p.998S>L and c.3550G>C p.1184D>H. Clinical monitoring is ongoing.
A medical history of presence of intermittent abdominal distention, presence of persistent generalized hypotonia, acute ascites manifestation, history of intermittent cerebral atrophy was documented. Genetic analysis confirmed gene variant W748S and c.3643+2T>C. Supportive care and follow-up were recommended.
Initial symptoms included diagnosed with hearing impairment, mild ascites detected. Subsequent investigations showed . Management involved both pharmacological and rehabilitative approaches.
A medical history of moderate ascites condition, persistent increased variability in muscle fiber diameter observed, acute cerebral atrophy symptoms, diagnosed with intermittent developmental regression was documented. Genetic analysis confirmed gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). Supportive care and follow-up were recommended.
A medical history of history of progressive failure to thrive in infancy, hearing impairment detected, persistent generalized hypotonia manifestation, clinical signs of moderate distal upper limb muscle weakness was documented. Genetic analysis confirmed gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). Supportive care and follow-up were recommended.
The patient presented to the clinic with progressive ascites observed, history of progressive generalized hypotonia, diagnosed with episodic cerebral atrophy, intermittent increased variability in muscle fiber diameter symptoms. Diagnostic workup revealed gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). Treatment was initiated accordingly.
Upon examination, acute distal upper limb muscle weakness manifestation, diagnosed with chronic hearing impairment, history of mild ophthalmoparesis, diagnosed with severe ascites were noted. Further imaging and laboratory tests identified gene variant c.3102delG (p.Lys1035Serfs*59) and c.3286C>T (p.Arg1096Cys). The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of persistent developmental regression detected. Laboratory evaluations detected gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Clinical monitoring is ongoing.
A medical history of diagnosed with acute cerebral atrophy, diagnosed with severe ophthalmoparesis was documented. Genetic analysis confirmed gene variant P765T. Supportive care and follow-up were recommended.
Initial symptoms included presence of severe ascites, clinical signs of distal upper limb muscle weakness, clinical signs of sudden cerebral atrophy. Subsequent investigations showed gene variant T251I/P587L and R807C. Management involved both pharmacological and rehabilitative approaches.
A medical history of moderate ascites condition, presence of sudden hearing impairment, clinical signs of moderate failure to thrive in infancy was documented. Genetic analysis confirmed gene variant W748S and c.3643+2T>C. Supportive care and follow-up were recommended.
The individual was admitted with complaints of ophthalmoparesis observed. Laboratory evaluations detected gene variant c.3286C>T (p.Arg1096Cys). Clinical monitoring is ongoing.
The individual was admitted with complaints of diagnosed with episodic failure to thrive in infancy, intermittent hearing impairment manifestation, presence of abdominal distention. Laboratory evaluations detected gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Clinical monitoring is ongoing.
A medical history of progressive increased variability in muscle fiber diameter observed, history of intermittent hearing impairment was documented. Genetic analysis confirmed gene variant A467T and W748S. Supportive care and follow-up were recommended.
The individual was admitted with complaints of chronic ascites detected, moderate increased variability in muscle fiber diameter observed, clinical signs of distal upper limb muscle weakness, moderate generalized hypotonia manifestation. Laboratory evaluations detected gene variant p.Arg627Gln and p.Arg852Cys. Clinical monitoring is ongoing.
The individual was admitted with complaints of episodic hearing impairment symptoms. Laboratory evaluations detected gene variant (c.2542G > A) p.G848S and (c.1399G > A) p.A467T. Clinical monitoring is ongoing.
Upon examination, progressive hearing impairment observed, mild abdominal distention symptoms, presence of episodic failure to thrive in infancy, persistent distal upper limb muscle weakness observed were noted. Further imaging and laboratory tests identified gene variant A467T and W748S. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of intermittent failure to thrive in infancy manifestation, distal upper limb muscle weakness manifestation. Laboratory evaluations detected gene variant W748S. Clinical monitoring is ongoing.
Upon examination, mild hearing impairment detected, ophthalmoparesis were noted. Further imaging and laboratory tests identified gene variant c.1535A>T p.K512M. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with cerebral atrophy observed, persistent ophthalmoparesis condition, severe increased variability in muscle fiber diameter observed. Diagnostic workup revealed gene variant T251I/P587L and R807C. Treatment was initiated accordingly.
Initial symptoms included episodic cerebral atrophy condition, chronic developmental regression. Subsequent investigations showed gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with severe ascites, chronic developmental regression symptoms. Diagnostic workup revealed gene variant 1399G→A (A467T). Treatment was initiated accordingly.
The individual was admitted with complaints of diagnosed with intermittent developmental regression, diagnosed with moderate distal upper limb muscle weakness. Laboratory evaluations detected gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). Clinical monitoring is ongoing.
The individual was admitted with complaints of acute distal upper limb muscle weakness symptoms, chronic generalized hypotonia. Laboratory evaluations detected gene variant 1399G>A A467T and 3573G>T K1191N. Clinical monitoring is ongoing.
The patient presented to the clinic with severe ophthalmoparesis, progressive developmental regression symptoms, hearing impairment condition. Diagnostic workup revealed gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). Treatment was initiated accordingly.
Initial symptoms included severe ascites, intermittent ophthalmoparesis condition. Subsequent investigations showed gene variant 1399G>A A467T and 3573G>T K1191N. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of mild generalized hypotonia detected. Laboratory evaluations detected gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Clinical monitoring is ongoing.
A medical history of clinical signs of mild distal upper limb muscle weakness, history of sudden ascites, history of persistent hearing impairment, severe increased variability in muscle fiber diameter manifestation was documented. Genetic analysis confirmed gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Supportive care and follow-up were recommended.
Initial symptoms included intermittent developmental regression symptoms. Subsequent investigations showed gene variant p.Arg953Cys. Management involved both pharmacological and rehabilitative approaches.
Upon examination, persistent increased variability in muscle fiber diameter observed, presence of chronic generalized hypotonia were noted. Further imaging and laboratory tests identified gene variant c. 2243G>C (p. W748S). The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with presence of sudden ophthalmoparesis. Diagnostic workup revealed gene variant A467T and W748S. Treatment was initiated accordingly.
The individual was admitted with complaints of severe failure to thrive in infancy detected, moderate ascites symptoms. Laboratory evaluations detected gene variant c.679C>T p.R227W and c.2542G>A p.G848S. Clinical monitoring is ongoing.
A medical history of diagnosed with chronic ophthalmoparesis, diagnosed with mild distal upper limb muscle weakness, acute failure to thrive in infancy symptoms was documented. Genetic analysis confirmed gene variant c.2243G>C. Supportive care and follow-up were recommended.
The patient presented to the clinic with presence of progressive generalized hypotonia, mild cerebral atrophy detected, severe increased variability in muscle fiber diameter detected. Diagnostic workup revealed gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Treatment was initiated accordingly.
Upon examination, acute cerebral atrophy condition were noted. Further imaging and laboratory tests identified gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with intermittent increased variability in muscle fiber diameter, ascites. Diagnostic workup revealed gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). Treatment was initiated accordingly.
Upon examination, presence of acute distal upper limb muscle weakness, persistent hearing impairment detected, episodic failure to thrive in infancy observed were noted. Further imaging and laboratory tests identified gene variant c.2993C>T p.998S>L and c.3550G>C p.1184D>H. The patient was started on a tailored therapeutic plan.
A medical history of clinical signs of sudden abdominal distention, clinical signs of severe cerebral atrophy was documented. Genetic analysis confirmed gene variant R853W and G737R. Supportive care and follow-up were recommended.
A medical history of chronic failure to thrive in infancy detected, episodic ophthalmoparesis condition was documented. Genetic analysis confirmed gene variant 1399G>A A467T and 3573G>T K1191N. Supportive care and follow-up were recommended.
Upon examination, presence of mild generalized hypotonia, diagnosed with developmental regression were noted. Further imaging and laboratory tests identified gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of mild distal upper limb muscle weakness manifestation, generalized hypotonia condition, presence of severe failure to thrive in infancy. Laboratory evaluations detected gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Clinical monitoring is ongoing.
Upon examination, clinical signs of progressive cerebral atrophy were noted. Further imaging and laboratory tests identified gene variant A467T and W748S. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with diagnosed with persistent increased variability in muscle fiber diameter. Diagnostic workup revealed gene variant c.2243G>C. Treatment was initiated accordingly.
The patient presented to the clinic with diagnosed with intermittent ascites. Diagnostic workup revealed gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). Treatment was initiated accordingly.
The patient presented to the clinic with presence of moderate generalized hypotonia, cerebral atrophy observed, clinical signs of sudden failure to thrive in infancy. Diagnostic workup revealed gene variant R853W and G737R. Treatment was initiated accordingly.
The patient presented to the clinic with clinical signs of mild developmental regression, severe distal upper limb muscle weakness detected. Diagnostic workup revealed gene variant 1868T>G  L623W and 2263A>G K755E. Treatment was initiated accordingly.
Initial symptoms included history of episodic ascites, acute generalized hypotonia symptoms, acute cerebral atrophy condition, diagnosed with hearing impairment. Subsequent investigations showed gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. Management involved both pharmacological and rehabilitative approaches.
A medical history of diagnosed with moderate ophthalmoparesis, diagnosed with severe increased variability in muscle fiber diameter, diagnosed with developmental regression was documented. Genetic analysis confirmed gene variant R853W and G737R. Supportive care and follow-up were recommended.
The patient presented to the clinic with episodic cerebral atrophy condition, increased variability in muscle fiber diameter symptoms, sudden hearing impairment manifestation, diagnosed with chronic generalized hypotonia. Diagnostic workup revealed gene variant c.3286C>T (p.Arg1096Cys). Treatment was initiated accordingly.
The individual was admitted with complaints of chronic distal upper limb muscle weakness manifestation, increased variability in muscle fiber diameter observed, diagnosed with episodic ascites. Laboratory evaluations detected gene variant c.2584G>A p.A862T and c.830A>T p.H277L. Clinical monitoring is ongoing.
A medical history of sudden failure to thrive in infancy symptoms was documented. Genetic analysis confirmed . Supportive care and follow-up were recommended.
Upon examination, ascites condition, severe ophthalmoparesis detected, severe cerebral atrophy observed, intermittent generalized hypotonia manifestation were noted. Further imaging and laboratory tests identified gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with severe ascites symptoms, episodic cerebral atrophy symptoms. Diagnostic workup revealed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Treatment was initiated accordingly.
Initial symptoms included clinical signs of sudden developmental regression. Subsequent investigations showed gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with clinical signs of severe hearing impairment. Diagnostic workup revealed gene variant c.2243G>C p.Trp748Ser. Treatment was initiated accordingly.
The patient presented to the clinic with mild generalized hypotonia symptoms, moderate cerebral atrophy manifestation. Diagnostic workup revealed gene variant 1399G>A A467T and 3573G>T K1191N. Treatment was initiated accordingly.
Upon examination, acute developmental regression, ophthalmoparesis manifestation were noted. Further imaging and laboratory tests identified . The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of presence of acute ascites, intermittent failure to thrive in infancy detected. Laboratory evaluations detected gene variant c.3102delG (p.Lys1035Serfs*59) and c.3286C>T (p.Arg1096Cys). Clinical monitoring is ongoing.
The patient presented to the clinic with clinical signs of episodic abdominal distention. Diagnostic workup revealed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Treatment was initiated accordingly.
The patient presented to the clinic with mild ophthalmoparesis manifestation, increased variability in muscle fiber diameter manifestation. Diagnostic workup revealed gene variant c.1399G>A (p.A467T) and c.3285C>G (p.S1095R). Treatment was initiated accordingly.
The patient presented to the clinic with presence of progressive generalized hypotonia, history of intermittent ascites, presence of mild distal upper limb muscle weakness, persistent abdominal distention detected. Diagnostic workup revealed gene variant c.2243G>C p.Trp748Ser. Treatment was initiated accordingly.
Initial symptoms included presence of progressive developmental regression, presence of progressive ascites. Subsequent investigations showed gene variant W748S. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included history of developmental regression, diagnosed with progressive abdominal distention, acute failure to thrive in infancy manifestation. Subsequent investigations showed . Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of hearing impairment observed. Laboratory evaluations detected gene variant W748S. Clinical monitoring is ongoing.
Upon examination, diagnosed with progressive failure to thrive in infancy, mild distal upper limb muscle weakness were noted. Further imaging and laboratory tests identified gene variant c.3643+1G>A and c.2396C>A (p.S799Y). The patient was started on a tailored therapeutic plan.
Initial symptoms included severe ascites observed, diagnosed with persistent developmental regression, diagnosed with progressive failure to thrive in infancy. Subsequent investigations showed gene variant A467T and W748S. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included generalized hypotonia observed, diagnosed with mild developmental regression. Subsequent investigations showed gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Management involved both pharmacological and rehabilitative approaches.
Upon examination, severe ophthalmoparesis detected, clinical signs of persistent hearing impairment were noted. Further imaging and laboratory tests identified gene variant (c.2542G > A) p.G848S and (c.1399G > A) p.A467T. The patient was started on a tailored therapeutic plan.
Initial symptoms included history of moderate hearing impairment, diagnosed with moderate abdominal distention, presence of moderate ophthalmoparesis, diagnosed with sudden distal upper limb muscle weakness. Subsequent investigations showed gene variant c.2243G>C. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of history of ophthalmoparesis, increased variability in muscle fiber diameter. Laboratory evaluations detected gene variant 1399G >A A467T and 2243G >C W748S. Clinical monitoring is ongoing.
A medical history of presence of progressive ophthalmoparesis, persistent generalized hypotonia detected, acute ascites symptoms, acute hearing impairment symptoms was documented. Genetic analysis confirmed gene variant P765T. Supportive care and follow-up were recommended.
Initial symptoms included history of acute abdominal distention. Subsequent investigations showed . Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of moderate increased variability in muscle fiber diameter condition, acute cerebral atrophy manifestation, presence of severe abdominal distention, presence of intermittent developmental regression. Laboratory evaluations detected gene variant c.1399G>A (p.A467T) and c.3285C>G (p.S1095R). Clinical monitoring is ongoing.
The individual was admitted with complaints of presence of episodic failure to thrive in infancy, clinical signs of distal upper limb muscle weakness. Laboratory evaluations detected gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Clinical monitoring is ongoing.
The patient presented to the clinic with history of progressive distal upper limb muscle weakness. Diagnostic workup revealed gene variant C752T (T251I) and C1760T (P587L). Treatment was initiated accordingly.
A medical history of chronic cerebral atrophy observed, mild generalized hypotonia manifestation was documented. Genetic analysis confirmed gene variant c.3102delG (p.Lys1035Serfs*59) and c.3286C>T (p.Arg1096Cys). Supportive care and follow-up were recommended.
The patient presented to the clinic with mild cerebral atrophy, acute ophthalmoparesis observed, persistent increased variability in muscle fiber diameter condition. Diagnostic workup revealed gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. Treatment was initiated accordingly.
The individual was admitted with complaints of persistent cerebral atrophy manifestation, presence of sudden hearing impairment, history of severe ascites. Laboratory evaluations detected gene variant c.1288A>T and c.2752T>C. Clinical monitoring is ongoing.
Upon examination, presence of ascites, chronic ophthalmoparesis manifestation, progressive hearing impairment manifestation, clinical signs of intermittent generalized hypotonia were noted. Further imaging and laboratory tests identified gene variant c.1535A>T p.K512M. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with episodic ophthalmoparesis condition, history of episodic ascites, history of sudden distal upper limb muscle weakness, history of acute abdominal distention. Diagnostic workup revealed gene variant c.1535A>T p.K512M. Treatment was initiated accordingly.
Upon examination, intermittent generalized hypotonia observed were noted. Further imaging and laboratory tests identified gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). The patient was started on a tailored therapeutic plan.
Initial symptoms included diagnosed with sudden distal upper limb muscle weakness, moderate ascites manifestation, persistent hearing impairment symptoms. Subsequent investigations showed gene variant R853W and G737R. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included history of episodic ascites, intermittent abdominal distention, presence of acute cerebral atrophy, history of episodic hearing impairment. Subsequent investigations showed gene variant c.2584G>A p.A862T and c.830A>T p.H277L. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of episodic hearing impairment observed, history of sudden increased variability in muscle fiber diameter, diagnosed with mild cerebral atrophy. Laboratory evaluations detected gene variant Tyr955Cys. Clinical monitoring is ongoing.
A medical history of presence of persistent hearing impairment, progressive failure to thrive in infancy symptoms, clinical signs of acute increased variability in muscle fiber diameter was documented. Genetic analysis confirmed gene variant c.752C>T p.T251I and c.1760C>T p.P587L. Supportive care and follow-up were recommended.
Upon examination, diagnosed with moderate ascites were noted. Further imaging and laboratory tests identified gene variant A467T and W748S. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with episodic ophthalmoparesis manifestation, severe increased variability in muscle fiber diameter observed. Diagnostic workup revealed gene variant R853W and G737R. Treatment was initiated accordingly.
The patient presented to the clinic with presence of persistent ascites, intermittent cerebral atrophy detected. Diagnostic workup revealed gene variant c.2864A>G (p.Tyr955Cys). Treatment was initiated accordingly.
The patient presented to the clinic with chronic increased variability in muscle fiber diameter, progressive abdominal distention condition. Diagnostic workup revealed gene variant A467T. Treatment was initiated accordingly.
A medical history of clinical signs of mild generalized hypotonia was documented. Genetic analysis confirmed gene variant R853W and G737R. Supportive care and follow-up were recommended.
The individual was admitted with complaints of sudden cerebral atrophy condition. Laboratory evaluations detected gene variant A467T. Clinical monitoring is ongoing.
The patient presented to the clinic with persistent ascites manifestation, generalized hypotonia, presence of mild hearing impairment, severe failure to thrive in infancy detected. Diagnostic workup revealed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Treatment was initiated accordingly.
A medical history of episodic failure to thrive in infancy symptoms, history of episodic distal upper limb muscle weakness was documented. Genetic analysis confirmed gene variant c.2243G>C. Supportive care and follow-up were recommended.
Upon examination, history of severe abdominal distention, mild ascites, clinical signs of acute failure to thrive in infancy were noted. Further imaging and laboratory tests identified gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). The patient was started on a tailored therapeutic plan.
Initial symptoms included episodic increased variability in muscle fiber diameter observed, severe hearing impairment detected, clinical signs of mild generalized hypotonia, history of intermittent ascites. Subsequent investigations showed gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with episodic hearing impairment symptoms, diagnosed with severe developmental regression. Diagnostic workup revealed gene variant A467T. Treatment was initiated accordingly.
The individual was admitted with complaints of history of progressive ophthalmoparesis. Laboratory evaluations detected gene variant A467T and W748S. Clinical monitoring is ongoing.
The individual was admitted with complaints of history of chronic hearing impairment. Laboratory evaluations detected gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. Clinical monitoring is ongoing.
Initial symptoms included presence of progressive failure to thrive in infancy. Subsequent investigations showed gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Management involved both pharmacological and rehabilitative approaches.
A medical history of clinical signs of episodic cerebral atrophy was documented. Genetic analysis confirmed gene variant c.3102delG (p.Lys1035Serfs*59) and c.3286C>T (p.Arg1096Cys). Supportive care and follow-up were recommended.
The patient presented to the clinic with moderate generalized hypotonia observed, history of ophthalmoparesis. Diagnostic workup revealed . Treatment was initiated accordingly.
The individual was admitted with complaints of diagnosed with episodic generalized hypotonia, severe ophthalmoparesis symptoms, history of sudden ascites. Laboratory evaluations detected gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Clinical monitoring is ongoing.
The patient presented to the clinic with history of severe increased variability in muscle fiber diameter, moderate abdominal distention detected. Diagnostic workup revealed gene variant p.Arg627Gln and p.Arg852Cys. Treatment was initiated accordingly.
Initial symptoms included distal upper limb muscle weakness detected, presence of severe failure to thrive in infancy. Subsequent investigations showed gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included episodic ophthalmoparesis detected. Subsequent investigations showed gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with diagnosed with acute ophthalmoparesis. Diagnostic workup revealed gene variant A467T and W748S. Treatment was initiated accordingly.
Upon examination, diagnosed with intermittent ascites, chronic generalized hypotonia detected, sudden hearing impairment, diagnosed with moderate developmental regression were noted. Further imaging and laboratory tests identified gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of mild increased variability in muscle fiber diameter detected, persistent failure to thrive in infancy, intermittent developmental regression symptoms, sudden cerebral atrophy observed. Laboratory evaluations detected . Clinical monitoring is ongoing.
The individual was admitted with complaints of acute developmental regression detected, ascites manifestation, clinical signs of severe generalized hypotonia, presence of moderate hearing impairment. Laboratory evaluations detected gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Clinical monitoring is ongoing.
The individual was admitted with complaints of moderate hearing impairment observed, intermittent distal upper limb muscle weakness symptoms, clinical signs of sudden abdominal distention. Laboratory evaluations detected gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Clinical monitoring is ongoing.
The individual was admitted with complaints of history of persistent cerebral atrophy. Laboratory evaluations detected gene variant R853W and G737R. Clinical monitoring is ongoing.
Upon examination, persistent distal upper limb muscle weakness detected were noted. Further imaging and laboratory tests identified gene variant (c.2542G > A) p.G848S and (c.1399G > A) p.A467T. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with history of severe ascites, sudden distal upper limb muscle weakness detected, episodic developmental regression manifestation, sudden hearing impairment observed. Diagnostic workup revealed gene variant C752T (T251I) and C1760T (P587L). Treatment was initiated accordingly.
A medical history of sudden cerebral atrophy detected, progressive abdominal distention manifestation was documented. Genetic analysis confirmed gene variant c.2584G>A p.A862T and c.830A>T p.H277L. Supportive care and follow-up were recommended.
The individual was admitted with complaints of diagnosed with moderate abdominal distention, progressive cerebral atrophy condition, chronic distal upper limb muscle weakness observed. Laboratory evaluations detected gene variant R853W and G737R. Clinical monitoring is ongoing.
The patient presented to the clinic with acute ophthalmoparesis detected, persistent developmental regression condition. Diagnostic workup revealed gene variant (c.2542G > A) p.G848S and (c.1399G > A) p.A467T. Treatment was initiated accordingly.
